|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-11-30
|
|
pubmed:abstractText |
Because human claudin-3 and claudin-4 (CLDN3 and CLDN4) are overexpressed in a variety of carcinomas, they are promising targets for cancer therapy. The aim of the present study was to generate a dual-targeting monoclonal antibody against CLDN3 and CLDN4 and evaluate its antitumour activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4555-62
|
|
pubmed:meshHeading |
pubmed-meshheading:21115905-Amino Acid Sequence,
pubmed-meshheading:21115905-Animals,
pubmed-meshheading:21115905-Antibodies, Monoclonal,
pubmed-meshheading:21115905-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:21115905-Breast Neoplasms,
pubmed-meshheading:21115905-CHO Cells,
pubmed-meshheading:21115905-Cell Line,
pubmed-meshheading:21115905-Cell Proliferation,
pubmed-meshheading:21115905-Cricetinae,
pubmed-meshheading:21115905-Cricetulus,
pubmed-meshheading:21115905-Cytotoxicity, Immunologic,
pubmed-meshheading:21115905-Female,
pubmed-meshheading:21115905-Flow Cytometry,
pubmed-meshheading:21115905-Humans,
pubmed-meshheading:21115905-Membrane Proteins,
pubmed-meshheading:21115905-Mice,
pubmed-meshheading:21115905-Mice, Inbred BALB C,
pubmed-meshheading:21115905-Mice, Inbred ICR,
pubmed-meshheading:21115905-Mice, SCID,
pubmed-meshheading:21115905-Molecular Sequence Data,
pubmed-meshheading:21115905-Ovarian Neoplasms,
pubmed-meshheading:21115905-Sequence Homology, Amino Acid,
pubmed-meshheading:21115905-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4.
|
|
pubmed:affiliation |
Antibody Research Laboratories, Kyowa Hakko Kirin Co Ltd, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
